Ardent Health, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
ARDT$17.93-0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows for the and
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net income | $156,564 | $155,873 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Depreciation and amortization | 125,387 | 114,666 |
| Other non-operating (gains) losses | (1,886) | 1,275 |
| Loss on extinguishment and modification of debt | — | 515 |
| Amortization of deferred financing costs and debt discounts | 2,432 | 3,568 |
| Deferred income taxes | 10,202 | 14,884 |
| Equity-based compensation | 24,194 | 30,183 |
| Income from non-consolidated affiliates | (12,251) | (1,409) |
| Changes in operating assets and liabilities, net of effect of acquisitions and divestitures: | ||
| Accounts receivable | (9,129) | 16,594 |
| Inventories | 1,961 | (6,308) |
| Prepaid expenses and other current assets | 54,879 | (47,361) |
| Accounts payable and other accrued expenses and liabilities | (79,925) | (15,716) |
| Accrued salaries and benefits | (13,988) | (19,689) |
| Net cash provided by operating activities | 258,440 | 247,075 |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (115,576) | (127,909) |
| Other | 8,357 | (92) |
| Net cash used in investing activities | (107,219) | (128,001) |
| Cash flows from financing activities: | ||
| Proceeds from insurance financing arrangements | 23,493 | 15,607 |
| Payments of principal on insurance financing arrangements | (14,434) | (10,751) |
| Payments of principal on long-term debt | (10,778) | (4,506) |
| Debt issuance costs | — | (2,573) |
| Distributions to noncontrolling interests | (68,371) | (62,366) |
| Repurchase of common stock | (24,011) | — |
| Other | (483) | (1,829) |
| Net cash used in financing activities | (94,584) | (66,418) |
| Net increase in cash and cash equivalents | 56,637 | 52,656 |
| Cash and cash equivalents at beginning of period | 709,601 | 556,785 |
| Cash and cash equivalents at end of period | $766,238 | $609,441 |
| Supplemental Cash Flow Information: | ||
| Non-cash purchases of property and equipment | $693 | $13,509 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.